Well Health - Digitale Services für die Medizin (Seite 2)
eröffnet am 12.11.22 11:39:23 von
neuester Beitrag 17.06.24 16:27:06 von
neuester Beitrag 17.06.24 16:27:06 von
Beiträge: 114
ID: 1.364.777
ID: 1.364.777
Aufrufe heute: 16
Gesamt: 8.747
Gesamt: 8.747
Aktive User: 0
ISIN: CA94947L1022 · WKN: A2JQV6 · Symbol: W7V
2,9390
EUR
+2,87 %
+0,0820 EUR
Letzter Kurs 09:17:50 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
21.03.24 · IRW Press |
30.11.23 · IRW Press |
14.11.23 · IRW Press |
Werte aus der Branche Finanzdienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 28,40 | +68,55 | |
| 9,0000 | +28,57 | |
| 10,010 | +14,27 | |
| 5,2000 | +12,55 | |
| 9,1360 | +10,87 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 24,001 | -10,94 | |
| 0,5548 | -11,91 | |
| 6,7700 | -13,28 | |
| 1,0775 | -20,19 | |
| 57,37 | -24,63 |
Beitrag zu dieser Diskussion schreiben
Feedback
interessant sind auch die Kommentare des Vorstands
https://well.company/wp-content/uploads/2024/05/2024Q1MDA.pd…
https://well.company/wp-content/uploads/2024/05/2024Q1MDA.pd…
es läuft alles nach oben
ausser dem Kurs ... Well ist wohl bei vielen noch nicht auf dem Radar 😕Vancouver, BC - May 8, 2024
WELL achieved record quarterly revenues of $231.6 million in Q1-2024, an increase of 37% as compared to Q1-2023 driven by acquisitions and organic growth of 13% which includes growth related to our clinic absorption program.
WELL achieved Adjusted EBITDA¹ of $28.3 million in Q1-2024, an increase of 6% as compared to Q1-2023. WELL’s Canadian business grew its Adjusted EBITDA in Q1- 2024 by 19% to $14.6 million on a YoY basis.
WELL achieved Net Income of $19.6 million or $0.06 per share in Q1-2024 as compared to a loss of $10.6 million in Q1-2023 and Adjusted Net Income¹ of $20.2 million or $0.08 per share, 43% higher than Q1-2023.
WELL achieved free cashflow available to shareholders or “FCFA2S“ per share of $0.0511 a 11% increase over Q1-2023. WELL is pleased to provide guidance of an improvement of FCFA2S of more than $55M in 2024, a 30% increase from $42.4 million in 2023.
WELL increases its guidance range for 2024 annual revenue of between $960 million to $980 million, while guiding to upper range of its previous Adjusted EBITDA¹ guidance of $125 million to $130 million.
...
https://well.company/wp-content/uploads/2024/05/2024Q1FS.pdf
moin an Winston und andere wenn denn andere da sind 😀 morgen kommen die Zahlen für das erste Quartal. Dann ein webcall nur als Info. Also aufgepasst 😉
Antwort auf Beitrag Nr.: 75.727.167 von Chash-Carry am 03.05.24 17:13:15Entweder bezahlt von Well, denke aber eher die Betreiber von w:o haben sich selber mit ein paar Aktien eingedeckt 
Zitat von Chash-Carry: Was mir auffällt ist das die Well Health Tech und die Tochtergesellschaft jetzt häufig hier als Schlagzeile laufen. Was steckt dahinter??? Hat einer eine Idee 💡? Das gute ist in Kanada werden viel mehr gehandelt als bei uns. 😀
Was mir auffällt ist das die Well Health Tech und die Tochtergesellschaft jetzt häufig hier als Schlagzeile laufen. Was steckt dahinter??? Hat einer eine Idee 💡? Das gute ist in Kanada werden viel mehr gehandelt als bei uns. 😀
Trading Spotlight
Das sind gute Nachrichten. Also umtriebig sind die ja. Da kann man echt nichts sagen. Bin mal gespannt ob die ihre KI Firma mit einbinden. Das würde einen erheblichen Mehrwert bringen. Denke so günstig wird mal bald keine Stücke mehr bekommen. NmM
good news ...
WELL Health Technologies Announces Collaboration with Microsoft to Accelerate Healthcare's Digital TransformationThe collaboration aims to improve North American healthcare by integrating Microsoft Azure and its AI with WELL's digital health platform to improve clinical outcomes, optimize costs, and ensure top-tier data privacy and security.
The integration is expected to streamline WELL's cloud and infrastructure environments and position it to improve its ability to scale and offer leading edge solutions across all of its business units, with an emphasis on Canada.
VANCOUVER, BC, April 30, 2024 /CNW/ - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL" or "the Company"), a company focused on positively impacting health outcomes by leveraging technology to empower healthcare providers and their patients globally, is pleased to announce it is collaborating with Microsoft to accelerate healthcare's digital transformation. This five-year agreement is set to accelerate the digital transformation of healthcare delivery across North America and beyond, integrating Microsoft Cloud and AI capabilities with WELL's comprehensive digital health platform to innovate and enhance the healthcare experience for both providers and patients. A key focus will be to substantially elevate WELL's scalability and flexibility as part of its offerings, especially as its organic growth accelerates and it aims to help large enterprise clients such as those in public sector.
...
https://www.newswire.ca/news-releases/well-health-technologi…
Sehe das auch langfristig werde bei entsprechenden Kursen weiter aufstocken 😀
Down 15% Since Earnings: Is WELL Health a Good Stock to Buy?
Despite the near-term weakness, WELL Health offers excellent buying opportunities for long-term investors, given the expanding addressable markets and attractive valuation.
WELL Health Technologies (TSX:WELL) is a tech-enabled healthcare company that focuses on technologies and services to aid healthcare providers in improving patient outcomes. Last month, the company reported underwhelming fourth-quarter earnings, with its adjusted net income declining by 10%. The company’s lower-than-expected 2024 guidance weighed on its stock price. It has lost 14.6% of its stock value since reporting its fourth-quarter earnings and is trading at a discount of 40% compared to its 52-week high.
So, let’s assess whether the recent correction offers any buying opportunities in the stock by looking at its recent performance and growth prospects.
WELL’s fourth-quarter performance
In the fourth quarter, WELL Health’s revenue grew 48% to $231.2 million. The acquisitions over the last four quarters, solid organic growth in its virtual businesses, and higher patient visits at its primary care drove its top line. Amid the top-line growth, its gross profits increased by 26%. However, its gross margins fell 760 basis points to 43.7% amid increased lower-margin recruitment-related revenue.
Meanwhile, the company’s net income increased from $22.1 million to $33.8 million. However, after removing special items, its adjusted net income stood at $11.16 million, representing a 10.7% decline from the previous year’s quarter. Also, its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) stood at $30.8 million, a 13% increase from the previous year’s quarter. The company ended 2023 with cash and cash equivalents of $43.4 million, representing an 11.2% decline from the prior year’s quarter. Now, let’s look at its growth prospects.
WELL’s growth prospects
The digitization of clinical procedures and the growing popularity of virtual healthcare services have created a multi-year growth potential for WELL Health. Meanwhile, the Vancouver-based company has continued its expansion by signing an agreement to acquire 10 primary care medical clinics in Ontario and British Columbia from Shoppers Drug Mart. The acquisitions could add around $8 million to its annual revenue. Earlier, the company had acquired Proack Security and Cycura, strengthening its capabilities to safeguard sensitive data and maintain robust security systems.
Besides, WELL Health is investing in AI (artificial intelligence) technology to develop new products and services that could enhance patients’ experience, thus driving organic growth. Along with these initiatives, the company also focuses on improving its profitability. So, it has implemented a cost-optimization program to improve its operational efficiency and drive profitability. Meanwhile, WELL Health has also strengthened its financial position by refinancing a credit facility of $300 million at favourable terms. So, it is well-equipped to fund its growth initiatives. The company expects to lower its debt levels, leverage ratio, and interest expenses this year. So, these initiatives could boost its financials.
Meanwhile, WELL Health’s management expects its top line to be $950-$970 million this year, with the midpoint representing a 24% increase from the previous year. Amid top-line growth, its adjusted EBITDA could grow 15%.
Investors’ takeaway
Amid the recent selloff, WELL Health’s valuation has declined to enticing levels, with its NTM (next-12-month) price-to-sales and NTM price-to-earnings multiples at 0.9 and 12.8, respectively. Despite the near-term weakness, I believe investors with a longer investment horizon can start accumulating the stock to earn superior returns in the long run.
...
https://www.fool.ca/2024/04/24/down-15-since-earnings-is-wel…
Despite the near-term weakness, WELL Health offers excellent buying opportunities for long-term investors, given the expanding addressable markets and attractive valuation.
WELL Health Technologies (TSX:WELL) is a tech-enabled healthcare company that focuses on technologies and services to aid healthcare providers in improving patient outcomes. Last month, the company reported underwhelming fourth-quarter earnings, with its adjusted net income declining by 10%. The company’s lower-than-expected 2024 guidance weighed on its stock price. It has lost 14.6% of its stock value since reporting its fourth-quarter earnings and is trading at a discount of 40% compared to its 52-week high.
So, let’s assess whether the recent correction offers any buying opportunities in the stock by looking at its recent performance and growth prospects.
WELL’s fourth-quarter performance
In the fourth quarter, WELL Health’s revenue grew 48% to $231.2 million. The acquisitions over the last four quarters, solid organic growth in its virtual businesses, and higher patient visits at its primary care drove its top line. Amid the top-line growth, its gross profits increased by 26%. However, its gross margins fell 760 basis points to 43.7% amid increased lower-margin recruitment-related revenue.
Meanwhile, the company’s net income increased from $22.1 million to $33.8 million. However, after removing special items, its adjusted net income stood at $11.16 million, representing a 10.7% decline from the previous year’s quarter. Also, its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) stood at $30.8 million, a 13% increase from the previous year’s quarter. The company ended 2023 with cash and cash equivalents of $43.4 million, representing an 11.2% decline from the prior year’s quarter. Now, let’s look at its growth prospects.
WELL’s growth prospects
The digitization of clinical procedures and the growing popularity of virtual healthcare services have created a multi-year growth potential for WELL Health. Meanwhile, the Vancouver-based company has continued its expansion by signing an agreement to acquire 10 primary care medical clinics in Ontario and British Columbia from Shoppers Drug Mart. The acquisitions could add around $8 million to its annual revenue. Earlier, the company had acquired Proack Security and Cycura, strengthening its capabilities to safeguard sensitive data and maintain robust security systems.
Besides, WELL Health is investing in AI (artificial intelligence) technology to develop new products and services that could enhance patients’ experience, thus driving organic growth. Along with these initiatives, the company also focuses on improving its profitability. So, it has implemented a cost-optimization program to improve its operational efficiency and drive profitability. Meanwhile, WELL Health has also strengthened its financial position by refinancing a credit facility of $300 million at favourable terms. So, it is well-equipped to fund its growth initiatives. The company expects to lower its debt levels, leverage ratio, and interest expenses this year. So, these initiatives could boost its financials.
Meanwhile, WELL Health’s management expects its top line to be $950-$970 million this year, with the midpoint representing a 24% increase from the previous year. Amid top-line growth, its adjusted EBITDA could grow 15%.
Investors’ takeaway
Amid the recent selloff, WELL Health’s valuation has declined to enticing levels, with its NTM (next-12-month) price-to-sales and NTM price-to-earnings multiples at 0.9 and 12.8, respectively. Despite the near-term weakness, I believe investors with a longer investment horizon can start accumulating the stock to earn superior returns in the long run.
...
https://www.fool.ca/2024/04/24/down-15-since-earnings-is-wel…
So war fleißig und habe meinen Einstieg auf knappe 2,5€ gedrückt. 😀 denke das ist relativ save. Wenn man bedenkt welche Beteiligung Well Health Tech an HealWell AI hat. Da ist der jetzige Börsenwert schon abgedeckt.
Durchsuchen
21.03.24 · IRW Press · WELL Health Technologies |
30.11.23 · IRW Press · WELL Health Technologies |
14.11.23 · IRW Press · CAD/USD |